



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 926 293 621
Organisasjonsform: Aksjeselskap
Foretaksnavn: GE HEALTHCARE NORGE AS
Forretningsadresse: Vitaminveien 1A
0485 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Georg Grøndalen
Dato for fastsettelse av årsregnskapet: 30.06.2025

Grunnlag for avgivelse

År 2024: Årsregnskapet er elektronisk innlevert
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 09.07.2025



Resultatregnskap

Beløp i: NOK	Note	2024	2023
RESULTATREGNSKAP			
Inntekter			
Sales revenues	2	286 869 000	298 283 000
Other operating income			157 000
Sum inntekter		286 869 000	298 440 000
Kostnader			
Raw materials and consumables		175 942 000	182 335 000
Employee benefits expense	3	58 877 000	58 064 000
Depreciations and amortisations		278 000	329 000
Nedskrivning av varige driftsmidler og immaterielle eiendeler	4		
Other expenses	3, 5	39 872 000	45 523 000
Sum kostnader		274 969 000	286 251 000
Driftsresultat		11 900 000	12 189 000
Finansinntekter og finanskostnader			
Income from subsidiaries	6		
Income from other group companies	6		
Group contribution received	6		
Renteinntekt fra foretak i samme konsern	6	7 374 000	5 339 000
Annen renteinntekt	6		
Sum finansinntekter		7 374 000	5 339 000
Impairment of shares in subsidiaries	6		
Write-down of long-term investments	6		
Rentekostnad til foretak i samme konsern	6		
Annen rentekostnad	6	257 000	31 000
Other financial expenses		399 000	3 305 000
Sum finanskostnader		656 000	3 336 000
Netto finans		6 718 000	2 003 000
Resultat før skattekostnad		18 618 000	14 192 000
Income tax expense	7	4 229 000	3 249 000



Resultatregnskap

Beløp i: NOK	Note	2024	2023
Årsresultat		14 389 000	10 943 000
Årsresultat etter minoritetsinteresser		14 388 000	10 944 000
Overføringer og disponeringer			
Transferred from reserve for valuation variances	9		
Konsernbidrag	8	16 915 000	12 160 000
Avgitt konsernbidrag	8, 9		
Udekket tap	9		
Other equity	9		
Transfer to/from other equity	9	-2 527 000	-1 216 000
Sum overføringer og disponeringer		-19 442 000	-13 376 000



Balanse

Beløp i: NOK	Note	2024	2023
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Development	4		
Patents, licences, etc.	4, 10		
Utsatt skattefordel	7	9 387 000	8 845 000
Goodwill	4		
Sum immaterielle eiendeler		9 387 000	8 845 000
Varige driftsmidler			
Buildings and land	4		
Machinery and other equipment	4	392 000	670 000
Assets under construction	4		
Equipment and other movables	4		
Sum varige driftsmidler		392 000	670 000
Finansielle anleggsmidler			
Investering i datterselskap	11		
Investering i annet foretak i samme konsern	10		
Lån til foretak i samme konsern	10		
Investeringer i tilknyttet selskap	10		
Sum anleggsmidler		9 779 000	9 515 000
Omløpsmidler			
Varer			
Sum varer	12		
Fordringer			
Accounts receivables		94 092 000	94 879 000
Other current receivables		1 767 000	328 000
Konsernfordringer		169 217 000	152 336 000
Sum fordringer		265 076 000	247 543 000
Cash and cash equivalents	13		
Sum omløpsmidler		265 076 000	247 543 000



Balanse

Beløp i: NOK	Note	2024	2023
SUM EIENDELER		274 855 000	257 058 000
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Share capital	9	1 114 000	1 114 000
Overkurs	9	129 001 000	109 842 000
Annen innskutt egenkapital	9		
Sum innskutt egenkapital		130 115 000	110 956 000
Other equity	9		
Sum egenkapital		130 115 000	110 956 000
Gjeld			
Langsiktig gjeld			
Utsatt skatt	7		
Annen langsiktig gjeld			
Gjeld til kredittinstitusjoner	10		
Langsiktig konserngjeld	10		
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Konvertible lån		37 436 000	35 529 000
Sertifikatlån		11 233 000	8 276 000
Leverandørgjeld	10	71 198 000	62 692 000
Tax payable	7		
Public duties payable		15 347 000	26 444 000
Kortsiktig konserngjeld	10		1 075 000
Other current liabilities	14	13 328 000	16 051 000
Sum kortsiktig gjeld		148 542 000	150 067 000
Sum gjeld		148 542 000	150 067 000
SUM EGENKAPITAL OG GJELD		278 657 000	261 023 000



Balanse

Beløp i: NOK	Note	2024	2023
---------------------	-------------	-------------	-------------



GE Healthcare Norge AS

Årsberetning 2024

VIRKSOMHETENS ART

Selskapets virksomhet er import, markedsføring, installasjon og service på medisinsk teknisk utstyr til offentlige og private sykehus og helseinstitusjoner. Den største delen av salget er til norske kunder (89% i år 2024). Selskapet har også noe salg til Island og Frankrike.

GE Healthcare Norge AS er et heleid datterselskap av GE Healthcare Holding Norge AS, et selskap eid (indirekte) av GE HealthCare Technologies Inc (GE HealthCare) i USA.

GE HealthCare ble offisielt skilt fra General Electric Company 3. januar 2023. Selskapets nye ultimate morselskap er GE HealthCare Technologies Inc, som erstatter General Electric Company (GE). GE HealthCare Holding LLC ble dannet som et aksjeselskap med begrenset ansvar i Delaware 16. mai 2022 med det formål å motta alle netto eiendeler til GE HealthCare. Den 29. desember 2022 konverterte GE HealthCare Holding LLC til et Delaware-selskap og ble omdøpt til GE HealthCare Technologies Inc. Separasjonen ble fullført 3. januar 2023 gjennom en distribusjon på omtrent 80,1 % av ordinære aksjer i GE HealthCare Technologies Inc til eiere av oversikt over GEs ordinære aksjer ved avslutning av virksomheten 16. desember 2022, og GE HealthCare Technologies Inc ble et uavhengig offentlig selskap, notert under symbolet "GEHC" på Nasdaq Stock Market LLC. Adressen til selskapets nye ultimate morselskap er 500 W. Monroe Street, Chicago, IL 60661, USA.

FORTSATT DRIFT

I samsvar med regnskapslovens § 3-3a bekreftes det at forutsetningen om fortsatt drift er lagt til grunn ved avleggelsen av årsregnskapet.

RESULTAT, INVESTERINGER, FINANSIERING OG LIKVIDITET

I år 2024 hadde selskapet en omsetning på 286,9 millioner NOK, noe som er en nedgang på 4% sammenlignet med år 2023 etter at det var en omsetningsvekst på 21 % fra år 2022 til 2023. Segmentet Imaging, som utgjør den største delen av omsetningen, hadde en vekst på 3%, drevet av god vekst i Norge. Island derimot hadde en reduksjon etter et eksepsjonelt bra 2023. I år 2024 utgjorde interne konserntransaksjoner 7% av omsetningen, sammenlignet med 5% i 2023.

De største kundene til GE Healthcare Norge AS er offentlige sykehus og inntektene fra år til år vil variere ut ifra sykehusenes anskaffelsesbehov og planer.

Driftsresultatet for år 2024 endte på 11,9 millioner NOK mot 12,2 millioner NOK i 2023. Det stabile resultatet viser at kostnadene er redusert i takt med inntektene.

Selskapets totale gjeld per 31.12.2024 var 149 millioner NOK, sammenlignet med 150 millioner NOK per 31.12.2023. Leverandørgjeld til eksterne var 11 millioner NOK i 2024 mot 14 millioner NOK i 2023, noe som anses adekvat for selskapets størrelse. Egenkapitalen utgjorde 47 % av totalkapitalen i 2024, mot 43% i 2023. Netto kontantstrøm fra operasjonelle aktiviteter var 16,9 millioner kroner i 2024, sammenlignet med 39,5 millioner kroner i 2023. Endringen skyldes hovedsakelig at det var store svingninger i både konserninterne balanser og kundefordringer i år 2023, og at kontantstrømmen i år 2024 er mer normalisert i forhold til selskapets årsresultat.

FINANSIELL RISIKO

Selskapet er utsatt for kredittisiko, renterisiko og valutarisiko i dens ordinære forretningsvirksomhet, og styrer mot å ha en akseptabel risiko innenfor disse områdene. Alle nye kunder blir kredittvurdert ved inngåelse av salgskontrakter. Salget skjer fortrinnsvis i lokal valuta, og gjeld i utenlandsk valuta betales



omgående. Selskapet har i all hovedsak rentebærende gjeld/ fordringer med flytende rentesats og er derfor eksponert for endringer i kortsiktige renter.

Selskapet dekker sitt finansieringsbehov gjennom den løpende driften og gjennom konsernets konsernkonto-ordning hvor likviditet kan plasseres og hentes. Selskapets finansieringsaktiviteter følges opp av den lokale finansavdelingen i samarbeid med den sentrale Treasury funksjonen i konsernet, og kontrolleres av foretakets ledelse og styre.

GE HealthCare har tegnet en felles ansvarsforsikring som styrets medlemmer og daglig leder er dekket av for deres mulige ansvar overfor foretaket og tredjepersoner.

ARBEIDSMILJØ OG PERSONALE

Sykefraværet endte på 6,04% i år 2024 sammenlignet med 0,62% i år 2023 og 2,0% i år 2022. Selv om det har vært en økning i år 2024 anses sykefraværet for å være på et gjennomsnittlig lavt nivå og følges opp i henhold til gjeldende regler. Det har ikke vært registrert noen arbeidsulykker eller skader på arbeidsplassen i år 2024.

REDGJØRELSE OM SAMFUNNSANSVAR

GE HealthCare støtter og respekterer internasjonale menneskerettsprinsipper og arbeider for å sikre at konsernet ikke er involvert i saker knyttet til brudd på menneskerettigheter. Dette gjør vi gjennom å respektere internasjonale og lokale arbeidsvilkår, tilby produkter som tilfredsstiller våre kunders behov så vel som gjeldende krav til sikkerhet og spesifikasjoner, og ved å kvalitetssikre våre kunder, leverandører og samarbeidspartnere.

GE HealthCare har retningslinjer som beskriver hvordan ansatte skal håndtere etiske spørsmål i forhold til kollegaer, leverandører og samarbeidspartnere. Alle nyansatte må gjennom opplæring for å bli bevisst på dette og å trenes opp i hvordan ulike situasjoner skal håndteres riktig.

Selskapet jobber aktivt med å bekjempe all form for korrupsjon. Som en del av GE HealthCare konsernet har vi robuste interne regnskapsprosesser og regelverk, og bruker betydelige ressurser på å sikre at dette overholdes. GE HealthCare forbyr uttrykkelig urettmessige betalinger i alle situasjoner og har implementert strukturerte og velfungerende kontrollprosesser for å sikre at dette ikke skjer.

Selskapet er omfattet av åpenhetsloven og har plikt til å publisere redegjørelse etter åpenhetsloven. Redegjørelsen er tilgjengelig på GE HealthCare konsernet sin nettside på følgende nettadresser:

https://www.gehealthcare.no/-/jssmedia/gehc/no/files/norway-transparency-act-2023-vf_-jb00191no.pdf?rev=-1

<https://www.gehealthcare.com/about/suppliers/terms-and-conditions>

REDGJØRELSE OM LIKESTILLING

Selskapets styre består av en kvinne og to menn. Ved utgangen av året er det 42 ansatte, hvorav 13 er kvinner.

Selskapet er tilfreds med kjønnsbalansen i arbeidsstokken. Vi tror på å fremme høyt kompetente personer til rett stilling til rett tid basert på praksis og holdninger, snarere enn å la kjønn være en avgjørende faktor. Kompetanse, holdninger og samarbeidsevner er de viktigste kriteriene for ansettelse og forfremmelse på alle nivåer. I rekrutteringssammenheng fokuserer vi på å sette sammen balanserte team med varierte kompetanse- og personlighetsprofiler, noe som styrker både kjønnsfordelingen og mangfoldet generelt.

I samsvar med GE HealthCare sin adferds kodeks skal selskapet og de ansatte medvirke til at det skapes en atmosfære der rettfærdige ansettelsesvilkår gjelder for alle medlemmer i et mangfoldig GE HealthCare-fellesskap.



MILJØRAPPORTERING

Selskapets virksomhet forurensar ikke det ytre miljø.

FREMTIDIG UTVIKLING

Selskapet streber etter å kontinuerlig å tilpasse seg markedet vi opererer i og ønsker å være i forkant av markedet hva gjelder trender og kompetanseheving. Selskapet har en god ordresreserve og det planlegges flere store produktlanseringer som vil være med på å ytterligere styrke vår posisjon i det Norske markedet. Vi arbeider med samkjøring av salgs og service organisasjonene innenfor GE Healthcare konsernet.

Det er ikke planlagt større investeringer eller omstruktureringer i år 2025. Selskapet vil løpende vurdere behovet for å tilpasse arbeidsstokken i takt med markedsutviklingen.

HENDELSER ETTER BALANSEDAGEN

Det har ikke inntruffet vesentlige forhold etter 31.12.2024 som er av betydning for bedømmelsen av selskapets stilling som ikke fremkommer av årsregnskapet med tilhørende noter.

ÅRSRESULTAT OG DISPONERINGER

Styret er av den oppfatning at årsregnskapet gir et rettviseende bilde over utviklingen og resultatet til selskapet samt selskapets eiendeler, gjeld og finansielle stilling.

Styret foreslår at overskuddet disponeres som følger:

Avgitt konsernbidrag (netto)	NOK	16 914 734
Overført fra annen innskutt EK	NOK	-2 527 097
Sum disponering (Årsresultat)	NOK	14 387 637

Oslo, 23.06.2025

I styret for GE Healthcare Norge AS,

Pål Arne Wøien
Styreleder

Ingvil Skoglund
Styremedlem

Gunnar Arveschoug
Styremedlem / Daglig Leder



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Profit and loss statement

	Note	01.01 - 31.12 2024	01.01 - 31.12 2023
REVENUES			
Sales revenue	2, 3	286 869	298 440
Total revenues		286 869	298 440
Operating expenses			
Cost of goods sold		175 942	182 335
Payroll expenses	4	58 877	58 064
Depreciation and amortization	5	278	329
Other operating expenses	6	39 872	45 523
Total operating expenses		274 970	286 250
Operating profit		11 899	12 190
FINANCIAL INCOME AND EXPENSES			
Interest received from group companies	3	7 374	5 339
Other financial expenses		-656	-3 337
Net financial income and expenses		6 718	2 002
Ordinary profit before tax		18 617	14 192
Tax expense	7	4 229	3 249
Ordinary profit after tax		14 387	10 944
Transfers			
Group contribution (net)	8	16 915	12 160
Transferred to other equity	8	-2 527	-1 216
Total		14 388	10 944



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Balance sheet

	Note	31.12.2024	31.12.2023
ASSETS			
NON-CURRENT ASSETS			
Intangible assets			
Deferred tax asset	7	9 387	8 845
Total intangible assets		9 387	8 845
Tangible assets			
Furniture, equipment and tools	5	392	670
Total tangible assets		392	670
Total non-current assets		9 779	9 516
CURRENT ASSETS			
Inventories	9	3 802	3 965
Receivables			
Trade receivables	3	94 092	94 879
Short term receivables from group companies	3	169 217	152 336
Other current receivables		1 767	328
Total receivables		265 075	247 542
Cash and cash equivalents	10	0	0
Total current assets		268 878	251 507
Total assets		278 656	261 023



GE Healthcare Norge AS Financial Statement 2024

All figures in NOK '000

Balance sheet

	Note	31.12.2024	31.12.2023
Equity and liabilities			
<i>Paid-in equity</i>			
Share capital	11	1 114	1 114
Other paid in equity	11	129 001	109 842
Total paid-in equity		130 115	110 956
<i>Earned equity</i>			
Retained earnings	11	0	0
Total earned equity		0	0
Total equity		130 115	110 956
LIABILITIES			
<i>CURRENT LIABILITIES</i>			
Trade payables	3	71 198	62 692
Public duties payable		15 347	26 444
Short term debt to group companies	3	0	1 075
Deferred income		11 233	8 276
Accruals for future obligations	12	37 436	35 529
Other current liabilities	13	13 328	16 051
Total current liabilities		148 541	150 066
Total liabilities		148 541	150 066
Total equity and liabilities		278 656	261 023

Oslo, 23 June 2025

Pal Arne Wøien
Chairman of the Board

Gunnar Arveschoug
General Manager / Board
Member

Ingvil Skoglund
Board Member



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Cash flow statement

	01.01 - 31.12 2024	01.01 - 31.12 2023
<i>Cash flow from operating activities</i>		
Result before tax	18 617	14 192
Depreciations	278	329
Changes in inventories	163	3 138
Changes in accounts receivable	787	-34 581
Changes in accounts payable	8 506	38 885
Changes in inter-company receivables and debt	-1 075	1 075
Changes in other accrued items	-10 396	16 515
Net cash flow from operating activities	16 881	39 553
<i>Cash flow from investing activities</i>		
Net change in cash pool receivable	-16 881	-39 553
Net cash flow from investment activities	-16 881	-39 553
<i>Cash flow from financing activities</i>		
Received group contribution	15 590	20 932
Distriuted group contribution	-15 590	-20 932
Net cash flow from financing activities	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents 01.01	0	0
Cash and cash equivalents 31.12	0	0
Net change in cash and cash equivalents	0	0



**GE Healthcare Norge AS
Financial Statement 2024**

All figures in NOK '000

Notes to financial statements

Note 1 - Accounting Principles

The annual accounts have been prepared in compliance with the Norwegian Accounting Act and Norwegian generally accepted accounting principles. The annual accounts are presented in thousand Norwegian kroner. Due to rounding off, smaller differences can occur in the totals.

The annual accounts are based on the basic principles of historical cost, comparability, going concern, congruence and prudence. Transactions are recorded at the value of the compensation at the time of the transaction. Revenues are recognized when they are earned and costs matched with earned income. The accounting principles will be explained below. When the actual number is not available at the time when preparing the accounts, the generally accepted accounting principles requires the best possible estimate to be calculated and used in the income statement and balance sheet. It could arise discrepancies between estimated and actual numbers.

Assets/liabilities that relate to the trade cycle and records that are due for payment within one year after the balance sheet date, are classified as current assets/current liabilities. Current assets/short-term debt are assessed to the lowest/highest value of acquisition cost and fair value. Fair value is defined as the estimated future sales price reduced with expected sales costs. Other assets are classified as fixed assets. Fixed assets is assessed at acquisition cost.

Revenue recognition time

Revenues are recognized when they are earned. Revenue recognition occurs normally at the time of delivery of goods and services. When the risk and title are transferred to the customer this is considered as the delivery time. The portion of the sales revenue that relates to future service benefits are capitalized as deferred income and then later recognized in line with the delivery of benefits. Operating revenues are deducted for sales tax, discounts, bonuses and invoiced shipping costs.

Matching / point in time for charge as expense

Expenses are matched with and charged to profits at the same time with the revenues the expenses can be attributed to. Expenses that can not be attributed directly to the revenue are recognized as costs when they are incurred.

Other operating income / expenses

Significant income and expenses that do not have the context of the ordinary course of business, are classified as other operating income and expenses. Records that are unusual, irregular and essential are classified as extraordinary.



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 1 - Accounting Principles (continued)

Fixed assets

Fixed assets are reflected in the balance sheet and depreciated to residual value over the assets expected useful life on a straight-line basis. If changes in the depreciation plan occur the effect is distributed over the remaining depreciation period. Direct maintenance of an asset is expensed under operating expenses as and when it is incurred. Additions or improvements are added to the assets cost price and depreciated together with the asset. The split between maintenance and additions/improvements is calculated in proportion to the assets condition at the acquisition date.

Impairment tests are carried out if there is indication that the carrying amount of an asset exceeds the estimated recoverable amount. The test is performed on the lowest level of fixed assets at which independent cashflows can be identified. If the carrying amount is higher than both the fair value less cost to sell and recoverable amount (net present value), the asset is written down to the highest of fair value less cost to sell and the recoverable amount.

Operating lease is charged as normal rental cost, and is classified as ordinary operating expenses.

Inventories and cost of goods sold

Inventories of goods are valued at the lower of purchase cost and fair value. This year's cost of goods sold consist of the purchase price sold merchandise and shipping charges. If invoices from the subcontractor are not received at the time of revenue recognition of sales then cost of goods sold is accrued. This will in the balance sheet be classified as short-term debt. Write-down for foreseeable obsolescence is included.

Guarantees

The preparation of financial statements in accordance with generally accepted accounting practice requires that management uses estimates and assumptions that affect the income statement and the valuation of assets and liabilities, as well as information about uncertain assets and liabilities at balance sheet date. Conditional losses that are probable and quantifiable is expensed as incurred.

Foreign currencies

Assets and liabilities in foreign currencies are valued at the exchange rate on the balance sheet date.

Receivables

Trade and other receivables are recorded on the balance sheet at the original invoiced amount net of accrual for expected losses. Accrued losses on receivables are being made based on individual assessments of the receivables.

Pension liabilities and pension cost

The company has a defined contribution pension plan that gives employees the right to agreed future pension benefits. Under the defined contribution scheme contributions are recognised as payroll expenses on a continuous basis. The payments are based on underlying wage levels and premium levels. The company has no pension obligations beyond the premium payment.



GE Healthcare Norge AS Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 1 - Accounting Principles (continued)

Deferred tax and tax expenses

The tax charge in the income statement include both payable taxes for the period and changes in deferred tax. Deferred tax is calculated at relevant tax rates on the basis of the temporary differences which exist between accounting and tax values, and any carryforward losses for tax purposes at the year-end. The effect of change in tax rates is disclosed in the notes. Tax enhancing or tax reducing temporary differences, which are reversed or may be reversed in the same period, have been eliminated. The disclosure of deferred tax benefits on net tax reducing differences which have not been eliminated, and carryforward losses, is based on estimated future earnings. Deferred tax and tax benefits which may be shown in the balance sheet are presented net.

Cash flow statement

The cash flow statement has been prepared according to the indirect method. Cash and cash equivalents include cash, bank deposits, and other short term investments which immediately and with minimal exchange risk can be converted into known cash amounts, with due date less than three months from purchase date. The company is a participant in the GE Healthcare cash pool arrangement and can draw on this by liquidity needs. No credit limit has been determined. The cash pool balance is classified as intercompany balance and interests are calculated on a daily basis.

Group financial statements

The company is part of the GE Healthcare Norway Group, owned by GE Healthcare Holding AS. The parent company of the Norway Group is GE Medical Holding AB (Sweden) that is member of the GE Healthcare Group, with ultimate parent of GE Healthcare Technologies Inc. listed on the Nasdaq Stock Market LLC from 3 January 2023, following the separation from General Electric Company.

GE Healthcare Technologies Inc. prepares annual consolidated financial statements based on US GAAP. These group financial statements include the GE Healthcare Norway Group. Based on this the Norway Group members have been granted the exemption to prepare consolidated financial statements. The group financial statements for GE Healthcare Technologies Inc. can be obtained from www.healthcare.com, or by enquiry to GE Healthcare Technologies Inc., with its principal address at 500 W Monroe Street, Chicago, IL 60661, USA.

Note 2 - REVENUES

	<u>2024</u>	<u>2023</u>
Area of operations		
Medical technical equipment	120 705	153 295
Services and parts	166 164	145 145
Total sales revenues	286 869	298 440
Total revenues	286 869	298 440
Geographical markets		
Norway	254 147	248 823
France	18 101	12 001
Iceland	11 854	35 941
Other Markets	2 766	1 676
Total revenues	286 869	298 440

The 2023 comparative revenue figures by geographical markets have been restated to correct a classification error identified in the prior year's disclosure.



GE Healthcare Norge AS Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 3 - TRANSACTIONS AND BALANCES WITH AFFILIATED COMPANIES

Profit and loss statement	Type of transaction	2024	2023
GE Medical Systems SCS	Revenues from goods / service sales	18 101	12 001
GE Vingmed Ultrasound AS	Revenues from goods / service sales	5 298	1 720
GE Healthcare Danmark A/S	Revenues from goods / service sales	605	1 185
GE Healthcare AS	Cash pool interest received	2 230	5 382
GE Healthcare Treasury Services UC	Cash pool interest received	5 144	0
GE Healthcare Treasury Services UC	Cash pool interest paid	0	-43
Net significant transactions with affiliated companies		31 379	20 245

Current receivables	Type of transaction	31.12.2024	31.12.2023
GE Vingmed Ultrasound AS	Trade receivables	0	17 516
GE Medical Systems SCS	Trade receivables	3 258	3 434
GE Healthcare AS	Trade receivables	18 062	3 477
Other GE affiliated companies	Trade receivables	585	107
Total trade receivables affiliated companies		21 904	24 534

Other receivables	Type of transaction	31.12.2024	31.12.2023
GE Healthcare AS	Cash pool receivable	0	152 336
GE Healthcare Treasury Services UC	Cash pool receivable	169 217	0
Total other receivables affiliated companies		169 217	152 336

Current liabilities	Type of transaction	31.12.2024	31.12.2023
GE Healthcare Trade and Development LLC	Trade payables	34 258	15 769
GE Vingmed Ultrasound AS	Trade payables	6 810	16 050
GE Medical Systems SCS	Trade payables	5 580	6 240
GE Healthcare Sverige AB	Trade payables	634	1 992
GE Healthcare Danmark A/S	Trade payables	782	2 563
GE Precision Healthcare LLC	Trade payables	4 364	1 540
GE Healthcare Technologies Inc.	Trade payables	3 978	2 006
Other GE affiliated companies	Trade payables	3 861	2 168
Total trade payables affiliated companies		60 267	48 328

Other current liabilities	Type of transaction	31.12.2024	31.12.2023
GE Healthcare Treasury Services UC	Cash pool payable	0	1 075
Total other current liabilities affiliated companies		0	1 075



GE Healthcare Norge AS Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

The company purchases most of its goods from various group companies within the Healthcare group for resale. Agreements with group companies have been established about service and maintenance work towards customers.

There is a shared service agreement in place with other group companies to purchase various support Services.

All contracts and transactions between group companies are conducted on market terms. The specified transaction groups / amount are considered to be the most significant ones for the understanding of the financial statements.

Note 4 - PERSONNEL EXPENSES, MANAGEMENT REMUNERATION AND AUDIT FEES

	<u>2024</u>	<u>2023</u>
Salaries, wages and other employee benefits		
Salaries and wages	44 678	45 006
Social security contribution	8 563	8 620
Pension costs	3 983	4 024
Other employee benefits	1 653	415
Total salaries, wages and other employee benefits	<u>58 877</u>	<u>58 064</u>

	<u>2024</u>	<u>2023</u>
Average number of full time employees during the year	40	42

	<u>2024</u>	<u>2023</u>
Management remuneration		
Salary and bonus expensed	1 815	1 993
Pension costs	129	113
Other benefits	176	192

The General Manager and the Chairman of the Board are member of the GE Healthcare group share option scheme. The scheme provides the assigned the right to buy a stock at face value to the given strike price. The option goes over in the employee's ownership and is thus entitled to dividend from no earlier than at the first redemption date, and no later than at the last redemption date. The expiration date is the last date the employee can realize the option. Options are funded by GE Healthcare Technologies Inc. and only the employer tax related to the option value are accounted for in the company.

Below is the number of options with corresponding strike price and redemption tune provided for the General Manager and the Chairman of the Board.



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 4 - PERSONNEL EXPENSES, MANAGEMENT REMUNERATION AND AUDIT FEES
(continued)

Number of options	Strike price USD	Assigned date	Expiry date
931	77	19 03 2018	19 03 2028
559	58	19 03 2019	19 03 2029
961	64	02 03 2020	02 03 2030
1 410	70	01 02 2023	01 02 2033
3 861			

In addition, the General Manager and the Chairman of the Board are also awarded Restricted Stock Units (RSU) with dividend rights Each RSU entitles the assigned (1) the right to receive a stock at face value USD 0 given certain restrictions, and (2) cash payments based on the dividends paid to the owners of such shares Until restrictions expire, or RSU's are cancelled, whatever occurs first, GE Healthcare will pay the assigned cash amounts equal to the number of times each RSU's share of the quarterly dividend payment provided to the shareholders of the ordinary shares Such payments should be completed fairly quickly after each quarterly payment date.

Number of RSU	Grant date	Restrictions expire
656	01 03 2022	01 03 2032
81	01 02 2023	01 02 2050
160	01 02 2023	01 02 2050
970	01 03 2024	01 03 2034
1 867		

No loans or guarantees have been granted to the General Manager or the Chairman of the Board.

No fees have been paid to the board members.

Auditor	2024	2023
Remuneration (ex VAT) for statutory audit of the financial year	230	227



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 6 - OTHER OPERATING EXPENSES

	2024	2023
Rental expenses	10 638	10 725
Travel and living expenses	7 392	9 080
Commission expenses	6 361	6 575
Transportation and storage costs	3 973	4 111
Consulting Services	4 171	3 123
Sundry office expenses	1 782	1 678
Guarantee expenses	13	3 676
Sales and advertising costs	247	661
Other operating expenses	5 294	5 893
Total other operating expenses	39 872	45 523

Note 7 - SPECIFICATION OF TAXES

	2024	2023
Calculation of taxable income		
Profit before tax	18 617	14 193
Permanent differences	608	575
Change in temporary differences	2 461	823
Total taxable income	21 686	15 590

Tax Payable	4 771	3 430
--------------------	--------------	--------------

	2024	2023
Tax expense for the year		
Tax payable on current year profit	4 771	3 430
Change in deferred tax asset	-541	-181
Change in deferred tax asset- change in tax rate	0	0
Total tax expense for the year	4 229	3 249

	2024	2023
Explanation of tax expense for the year		
Tax on profit before tax	4 096	3 122
Effect from permanent items	134	126
Effect from change in tax rate	0	0
Total tax expense for the year	4 229	3 248



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 7 - SPECIFICATION OF TAXES (continued)

	<u>31.12.2024</u>	<u>31.12.2023</u>
Tax payable in the balance sheet		
Tax payable on current year profit	4 771	3 430
Tax on paid group contribution	-4 771	-3 430
Total tax liability	<u>0</u>	<u>0</u>
	<u>31.12.2024</u>	<u>31.12.2023</u>
Specification of basis for deferred tax asset		
Fixed assets	-610	-328
Inventories	-4 373	-4 647
Receivables	-882	-494
Gain and loss account	633	792
Accruals	-37 436	-35 529
Total temporary differences	<u>-42 667</u>	<u>-40 206</u>
Deferred tax Asset	<u>9 387</u>	<u>8 845</u>

The Company, as the subsidiary of GE HealthCare Technologies Inc., is within the scope of the Organisation for Economic Co-operation and Development (OECD) Pillar Two model rules ("Pillar Two"). The Pillar Two legislation was enacted in Norway in January 2025, the jurisdiction in which the Company is incorporated. Upon enactment, the Pillar Two taxation regime (specifically the qualifying domestic minimum top-up tax ("QDMTT") came into effect from 1 January 2024, and the effective date of the income inclusion rule ("IIR") is 1 January 2024. The Undertaxed Profit rule ("UTPR") was enacted in January 2025, and will come into effect from 1 January 2025.

The Company has applied the exception to recognizing and disclosing information about deferred tax assets and liabilities related to Pillar Two income taxes. The results of the analysis indicated that the Company will not qualify for the transitional Country-by-Country Reporting (CbCR) safe harbor in 2024. However, the expense from the top-up tax included in the financial statements for the current year under Pillar Two is zero.

The Company's ultimate parent entity is domiciled in the United States. Although the United States has not adopted its respective Pillar Two legislation as of 31 December 2024, the exposure to incremental tax payable under any applicable undertaxed profit rule (UTPR) is not estimated to be significant.



GE Healthcare Norge AS Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

Note 8 - GROUP CONTRIBUTION

Current year the company submitted the following taxable group contribution.

Provider	Receiver	Gross	Net
GE Healthcare Norge AS	GE Healthcare Norway Holding AS	21 686	16 915

Current year the company received the following non-taxable group contribution.

Provider	Receiver	Gross
GE Healthcare Norway Holding AS	GE Healthcare Norge AS	21 686

Note 9 - INVENTORIES

	31.12.2024	31.12.2023
Stock of equipment	1 742	2 036
Equipment in transit	5 582	5 937
Stock of spare parts	851	639
Obsolescence	-4 373	-4 647
Total inventories	3 802	3 965

Note 10 - CASH AND CASH EQUIVALENTS

The company has a bank account in Danske Bank that is included in GE Healthcare group cash pool agreement. The balance is brought forward to GE Healthcare Treasury and converted into short term receivable from group companies. Interest is calculated based on arm's length principle.

The company also has a 5 000 000 NOK bank guarantee at DNB Bank as security for proper payment of employee withholding taxes. There are no restricted funds or collaterals at year end.

Note 11 - EQUITY

	Share capital	Other paid-in equity	Retained Earnings	Total Equity
Equity 31.12.2023	1 114	109 842	0	110 956
Current year profit / loss	0	0	14 388	14 388
Paid taxable group contribution	0	-2 527	-14 388	-16 915
Received non-taxable group contribution	0	21 686	0	21 686
Equity 31.12.2024	1 114	129 001	0	130 115

The share Capital consists of 1 114 000 shares of 1 000 NOK All shares have equal rights. The company's shares are 100 % owned by GE Vingmed Ultrasound AS.



GE Healthcare Norge AS
Financial Statement 2024

All figures in NOK '000

Notes to financial statements (continued)

NOTE 12 ACCRUALS FOR FUTURE OBLIGATIONS

	31.12.2024	31.12.2023
Provision for standard and extended warranty	37 436	35 529
Total accruals for future obligations	37 436	35 529

Warranty provision is an accounting accrual based on best estimate.

Note 13 OTHER CURRENT LIABILITIES

	31.12.2024	31.12.2023
Sales commissions and bonuses	6 194	7 458
Vacation pay	6 586	6 584
Freight accrual	353	580
Sales related accruals	-104	674
Other liabilities	299	755
Total Other Current Liabilities	13 328	16 051

Note 14 - PENSION COSTS AND LIABILITIES

The company has a defined contribution pension scheme that covers 41 people. It meets the requirements in the mandatory occupational pensions act. Contributions to the defined contribution scheme are recognized as expense in the profit and loss statement as incurred.

Additionally, the company has an agreed early retirement scheme (AFP). The AFP scheme is a tariff based lifelong retirement arrangement that can be withdrawn from the age of 62 organized by the main labour unions and the Norwegian state. It is a defined benefit multi-enterprise scheme, but is recognized in the accounts as a defined contribution scheme until reliable and sufficient information is available for the group to recognize its proportional share of pension cost, pension liability and pension funds in the scheme. The company's liabilities are therefore not recognised as debt in the balance sheet.

	2024	2023
AFP premium paid	542	687



Deloitte.

Deloitte AS
Dronning Eufemias gate
14
Postboks 221
NO-0103 Oslo
Norway

+47 23 27 90 00
www.deloitte.no

To the General Meeting of GE Healthcare Norge AS

INDEPENDENT AUDITOR'S REPORT

Opinion

We have audited the financial statements of GE Healthcare Norge AS (the Company), which comprise the balance sheet as at 31 December 2024, the income statement, statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements, and
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2024 and its financial performance and its cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report and the other information accompanying the financial statements. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report nor the other information accompanying the financial statements.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report and the other information accompanying the financial statements. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the other information accompanying the financial statements and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report and the other information accompanying the financial statements otherwise appears to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report or the other information accompanying the financial statements. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

Deloitte AS and Deloitte Advokatfirma AS are the Norwegian affiliates of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see www.deloitte.com/about to learn more about our global network of member firms.

Registrert i Foretaksregisteret
Medlemmer av Den norske Revisorforening
Organisasjonsnummer: 980 211 282

Deloitte Norway conducts business through two legally separate and independent limited liability companies; Deloitte AS, providing audit, consulting, financial advisory and risk management services, and Deloitte Advokatfirma AS, providing tax and legal services.



Deloitte.

Independent auditor's report
Ge Healthcare Norge AS

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error. We design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves a true and fair view.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Oslo, 27. June 2025
Deloitte AS



Deloitte.

Independent auditor's report
Ge Healthcare Norge AS

Morten Østigård
State Authorised Public Accountant
(electronically signed)



Independent auditor's report

Name	Date
Østigård, Morten	2025-06-27

Identification

 **bankID** Østigård, Morten



This document contains electronic signatures using EU-compliant PAdES - PDF
Advanced Electronic Signatures (Regulation (EU) No 910/2014 (eIDAS))



Revenue statement GE Healthcare Norge AS

Profit & Loss Statement	Note	2024	2023
Revenues			
Sales revenues	2	286 869	298 283
Other operating income		0	157
Total revenues		286 869	298 440
Operating expenses			
Raw materials and consumables		175 942	182 335
Employee benefits expense	3	58 877	58 064
Depreciations and amortisations		278	329
Other expenses	3, 5	39 872	45 523
Total operating expenses		274 970	286 250
Operating profit		11 899	12 190
Financial income and expenses			
Interest income from group companies	6	7 374	5 339
Other interest expenses		257	31
Other financial expenses		399	3 305
Net financial items		6 718	2 002
Net profit before tax		18 617	14 192
Income tax expense	7	4 229	3 249
Net profit after tax		14 388	10 944
Net profit or loss		14 388	10 944
Distribution of result			
Group contribution (net)	8	-16 915	-12 160
Transfer to/from other equity	9	2 527	1 216
Total distribution		14 388	10 944



Balance sheet GE Healthcare Norge AS

Balance sheet	Note	2024	2023
Assets			
<i>Non-current assets</i>			
<i>Intangible assets</i>			
Deferred tax asset	7	9 387	8 845
Total intangible assets		9 387	8 845
<i>Tangible assets</i>			
Machinery and other equipment	4	392	670
Total tangible assets		392	670
<i>Financial assets</i>			
Total non-current assets		9 779	9 516
<i>Current assets</i>			
Inventories	12	3 802	3 965
<i>Receivables</i>			
Accounts receivables		94 092	94 879
Other current receivables		1 767	328
Receivables from group companies		169 217	152 336
Total receivables		265 075	247 542
Total current assets		268 878	251 507
Total assets		278 656	261 023



Balance sheet GE Healthcare Norge AS

Balance sheet	Note	2024	2023
Equity and liabilities			
Equity			
<i>Paid-in capital</i>			
Share capital	9	1 114	1 114
Share premium reserve	9	129 001	109 842
Total paid-up equity		130 115	110 956
<i>Retained earnings</i>			
Total equity		130 115	110 956
Liabilities			
<i>Non-current liabilities</i>			
<i>Current liabilities</i>			
Accruals		37 436	35 529
Other current financial liabilities		11 233	8 276
Account payables	10	71 198	62 692
Public duties payable		15 347	26 444
Liabilities to group companies	10	0	1 075
Other current liabilities	14	13 328	16 051
Total current liabilities		148 541	150 066
Total liabilities		148 541	150 066
Total equity and liabilities		278 656	261 023

Oslo

The board of GE Healthcare Norge AS

Pål Arne Wøien
chairman of the board

Gunnar Arveschoug
member of the board/General Manager

Invild Skoglund
member of the board



Skattedirektoratet

Saksbehandler Rune Tystad	Deres dato 29.09.2016	Vår dato 11.11.2016
Telefon 977 59 464	Deres referanse Geir Atle Carlsen	Vår referanse 2016/996601

GENERAL ELECTRIC INTERNATIONAL INC filial av
utenlandsk foretak
Postboks 4766 Nydalen
0421 OSLO

Tillatelse til å utarbeide årsregnskap og årsberetning på engelsk språk for selskaper i General Electric-gruppen

Vi viser til deres brev av 29. september 2016 der dere søker om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk for følgende selskaper:

GE Healthcare AS,	org.nr. 914 829 674
GE Healthcare Holding AS,	org.nr. 987 015 225
Amersham Health Norge AS,	org.nr. 979 306 946
GE Healthcare Holding Norge AS,	org.nr. 988 963 755
GEFH AS,	org.nr. 990 400 156
GE Healthcare Clinical Systems Norway AS,	org.nr. 988 963 690
GE Healthcare Norge AS,	org.nr. 926 293 621
GE Vingmed Ultrasound AS,	org.nr. 938 937 583
GE Healthcare Europe GmbH - Branch Norway,	org.nr. 968 146 092
GE Capital AS,	org.nr. 987 058 765
GECAS Aircraft Leasing Norway AS,	org.nr. 985 551 685
GECAS EX-IM Leasing Norway AS,	org.nr. 894 570 652
GE Lighting AS,	org.nr. 910 904 396
Nuovo Pignone SPA NUF,	org.nr. 974 230 666
Vetco Gray Scandinavia AS,	org.nr. 990 441 545
Vetco Gray AS,	org.nr. 913 147 758
Presens AS,	org.nr. 976 876 385
Naxys AS,	org.nr. 993 277 983
Advantec AS,	org.nr. 887 471 282
NTOS Holding AS,	org.nr. 912 101 231
NTOS AS,	org.nr. 983 923 518
PII Ltd Norway Branch,	org.nr. 980 716 856
Thermodyn SAS Norway branch,	org.nr. 982 455 626
GE Energy (Norway) AS,	org.nr. 980 862 860
GE Wind Energy (Norway) AS,	org.nr. 881 520 532
Granite Services International Inc Norway branch,	org.nr. 985 604 908
GE Power Norway AS,	org.nr. 980 402 274

Postadresse
Postboks 9200 Grønland
0134 Oslo

Besøksadresse:
Se www.skatteetaten.no
Org.nr: 996250318
E-post: skatteetaten.no/sendepost

Sentralbord
800 80 000
Telefaks
22 17 08 60



GE Energy Connections AS,	org.nr. 937 025 440
GE Renewable Norway AS,	org.nr. 889 467 592
GE Energy Power Conversion France SAS Norway branch,	org.nr. 995 139 421
GE Energy Power Conversion Norway AS,	org.nr. 996 326 020
GE Energy Power Conversion UK Ltd Norway branch,	org.nr. 813 661 632
GE International Inc. NUF,	org.nr. 860 192 942

I tillegg søker dere om dispensasjon til å kunne utarbeide alle fremtidige selskapers årsregnskap og årsberetning på engelsk.

Skattedirektoratet gir på bakgrunn av en konkret helhetsvurdering de overnevnte selskaper dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen forutsetter at opplysningene som vedtaket baserer seg på ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Etter regnskapsloven § 3-4 tredje ledd kan det kun gis dispensasjon til navngitte regnskapspliktige, jf. definisjon av enkeltvedtak i forvaltningsloven § 2 første ledd bokstav b. Vi har derfor ikke hjemmel til å behandle søknaden knyttet til fremtidige selskaper. For å få dispensasjon for eventuelle fremtidige selskaper må dere søke konkret for de aktuelle selskapene.

Bakgrunn

Fra deres søknad gjengis:

General Electric Company er et børsnotert amerikansk konsern med virksomhet i mange land, herunder i Norge gjennom flere norske selskaper og filialer av utenlandske selskaper. Som et ledd i konsernets bestrebelser på å forenkle rapporteringer og informasjonsflyt, søkes det med dette om å få utarbeide årsregnskap og årsberetning på engelsk fra og med regnskapsåret 2016 for de selskaper og filialer som er spesifisert i vedlegg til denne søknaden.

De norske selskapene er lokalisert ulike steder i Norge, herunder Oslo, Sandvika, Horten, Stavanger og Bergensområdet og omfatter ulike typer bransjer. General Electric har ikke etablert en spesifikk konsernstruktur med en enkelt konsernspiss i Norge, men hvor det finnes flere delkonsern og enkeltstående selskaper avhengig av bransje.

Virksomheten er fullt ut rettet mot produksjon og salg av varer og tjenester til andre selskaper i Norge og utlandet. Det selges ikke noe direkte til forbrukere i Norge. Innenfor energi og olje/gass er General Electric aktive både på sokkelen og på land. Alle sentrale aktører og samarbeidspartnere er av internasjonal karakter, og innenfor bransjen beherskes og benyttes engelsk.



Innenfor helseområdet produseres det kontrastvæskemidler og ultralydmaskiner. Alt salg går til offentlige og private sykehus, leger og helseinstitusjoner. Det er i det alt vesentlige eksportrettet, med en liten andel salg og service i Norge, men ikke direkte mot forbrukermarkedet. Teknisk dokumentasjon, søknader om godkjenning i ulike land mv utarbeides på engelsk, og alle sentrale aktører innenfor bransjen benytter engelsk som arbeidsspråk.

Utover dette har man noen mindre virksomheter som blant annet forestår leasing av fly til utenlandske flyselskaper, salg av lysmateriell til grossister i Norge, samt utøver interne støttefunksjoner til norske og utenlandske konsernselskaper.

Selskapenes arbeidsspråk er engelsk, da man har tildels utstrakt samarbeid med andre konsernselskaper i utlandet. Dette forenkler og effektiviserer informasjonsflyt, analyser og rapporteringer, samt reduserer kostnader. Selskapene opererer i sektorer hvor engelsk er det klart dominerende språket. Morselskapets aksjonærer er utenlandske personer eller selskaper.

I flere av selskapene sitter det både norske og utenlandske styremedlemmer. Dette medfører at det i dag må utarbeides både norske og engelske versjoner av årsregnskaper og årsberetninger. Det er ressurskrevende, og kan også av og til gi opphav til tvil om oversettelse og uoverensstemmelser mellom engelsk og norsk versjon, og dermed unødvendige misforståelser.

Skattedirektoratets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap m.v., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i



proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter Skattedirektoratets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har Skattedirektoratet lagt særlig vekt på at selskapene og filialene inngår i et utenlandsk konsern og at selskapenes arbeidsspråk er engelsk. Videre er det vektlagt at selskapene opererer i sektorer hvor engelsk er det klart dominerende språket.

Vennligst oppgi vår referanse ved henvendelser i saken.

Med hilsen

Torstein Kinden Helleland
seniorrådgiver
Rettsavdelingen, foretaksskatt
Skattedirektoratet

Rune Tystad

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer